METHODS FOR ADMINISTRATION AND FORMULATIONS FOR THE TREATMENT OF REGIONAL ADIPOSE TISSUE
Provided herein are pharmaceutical formulations, methods, and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation comprising a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Formulations comprise a pharmaceutical formulation that is suitable for subcutaneous injection comprising: (a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist, or a salt thereof; and (b) at least one subcutaneously acceptable inactive ingredient.
1 . An aqueous formulation comprising a formulation suitable for subcutaneous injection that comprises:
(a) an adipose tissue-reducing lipophilic long-acting selective beta-2 adrenergic receptor agonist or a salt thereof, that comprises a dose of up to about 5 micrograms of the agonist and that is suitable for subcutaneous injection; and
(b) at least one subcutaneously acceptable inactive ingredient.
2 . The formulation of claim 1 wherein the formulation is formulated as a dose of about 5 ng to about 5 micrograms.
3 . The formulation of claim 1 wherein the formulation is formulated to be administered using a single needle, multiple needles, or a needleless injection device.
4 . The formulation of claim 1 wherein the dose of the beta-2 adrenergic receptor agonist is formulated to be administered through at least 2 sub-doses.
5 . The formulation of claim 1 wherein the dose of the beta-2 adrenergic receptor agonist is formulated to be administered through at least 10 sub-doses.
6 . The formulation of claim 1 wherein the lipophilic long-acting selective beta-2 adrenergic receptor agonist is salmeterol xinafoate.
7 . The formulation of claim 6 wherein the dose of salmeterol xinafoate is formulated to be administered through at least 2 sub-doses.
8 . The formulation of claim 7 wherein a single sub-dose comprises about 20 nanograms of salmeterol xinafoate.
9 . A method of treating a patient who has excess adipose tissue or reducing adipose tissue in a patient comprising subcutaneously administering to said patient a pharmaceutical formulation that is suitable for subcutaneous injection, the formulation comprising:
(a) an adipose tissue-reducing lipophilic long-acting selective beta-2 adrenergic receptor agonist or a salt thereof, that comprises a dose of up to about 5 micrograms of the agonist; and
(b) at least one subcutaneously acceptable inactive ingredient.
10 . The method of claim 9 wherein the formulation is administered as a dose of about 5 ng to about 5 micrograms of the beta-2 adrenergic receptor agonist.
11 . The method of claim 9 wherein the dose of the beta-2 adrenergic receptor agonist is administered through at least 2 sub-doses.
12 . The method of claim 9 wherein the lipophilic long-acting selective beta-2 adrenergic receptor agonist is salmeterol xinafoate.
13 . The method of claim 12 wherein the dose of salmeterol xinafoate is administered through at least 10 sub-doses.
14 . The method of claim 9 wherein the method is a method of treating a patient who has excess adipose tissue.
15 . The method of claim 9 wherein the method is a method of reducing adipose tissue in a patient.